Lansoprazole vs Pantoprazole: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Lansoprazole irreversibly inhibits the H+/K+ ATPase proton pump, raising gastric pH above 4.0 and eliminating the acidic environment essential for mineral and vitamin absorption. CTD documents 77 gene interactions — 3.5x more than pantoprazole — spanning drug transporter proteins, inflammatory pathway genes, and metabolic enzymes beyond just the proton pump. This broader molecular footprint suggests lansoprazole has off-target effects that may compound the nutrient depletion from acid suppression alone.
Lansoprazole achieves 81% oral bioavailability with a 1-hour half-life, reaching peak levels in 1.3 hours. Available in orally disintegrating tablet form for patients with swallowing difficulties.
- ✓Higher bioavailability (81%) than pantoprazole's 77% ensures more consistent acid suppression
- ✓ChEMBL documents 137 RCTs — slightly more clinical evidence than pantoprazole's 109
- ✓Orally disintegrating tablet option improves compliance for patients who can't swallow pills
- ✓Generic since 2009, making it cost-effective for long-term therapy plus supplementation
- ✗77 CTD gene interactions — 3.5x more than pantoprazole — indicate broader metabolic disruption
- ✗FAERS logs 163,009 adverse reports with 18.6% death-associated rate versus pantoprazole's 14.4%
- ✗Moderate CYP2C19 interaction potential may affect clopidogrel and other CYP-metabolized drugs
- ✗94.8% of FAERS reports classified as serious — higher than pantoprazole's 90.8%
Patients who need reliable acid suppression with good bioavailability and aren't taking CYP2C19-sensitive medications like clopidogrel.
Pantoprazole blocks the same proton pump but binds specifically to cysteine 822 — a more selective binding site. CTD documents only 22 gene interactions, and pantoprazole has the weakest CYP2C19 inhibition of any PPI, meaning it's the least likely to alter blood levels of co-prescribed medications. The six-nutrient depletion pattern is identical to lansoprazole: raising gastric pH impairs iron conversion, calcium dissolution, pepsin-dependent B12 cleavage, and pH-sensitive magnesium, zinc, and vitamin C absorption.
Pantoprazole has 77% bioavailability with a 1-hour half-life and 98% protein binding. Available in both oral and IV formulations — the IV form is the standard for stress ulcer prophylaxis in hospitalized patients.
- ✓Lowest CYP450 interaction potential of any PPI — safest choice alongside clopidogrel and warfarin
- ✓Only 22 CTD gene interactions — the most targeted PPI molecular profile after esomeprazole
- ✓Most prescribed PPI in the U.S. with extensive real-world safety data
- ✓IV formulation available for ICU stress ulcer prophylaxis when oral dosing isn't possible
- ✗FAERS logs 206,212 reports — the highest volume of any PPI — with 14.4% death-associated rate
- ✗Slightly lower bioavailability (77%) than lansoprazole may produce less consistent acid suppression
- ✗98% protein binding is the highest among PPIs — theoretical displacement interaction risk
- ✗Less potent acid suppression than esomeprazole for severe erosive esophagitis
Patients on antiplatelet therapy, complex medication regimens, or anyone who needs the most drug-interaction-friendly PPI at generic pricing.
Feature Comparison
| Feature | Lansoprazole | Pantoprazole |
|---|---|---|
| Drug Class | PPI (substituted benzimidazole) | PPI (pyridinylmethylsulfinyl benzimidazole) |
| Nutrients Depleted | 6 — Mg, Ca, Fe, B12, Zn, vitamin C | 6 — Mg, Ca, Fe, B12, Zn, vitamin C |
| CTD Gene Interactions | 77 documented | 22 documented |
| Bioavailability | 81% | 77% |
| CYP Drug Interaction Risk | Moderate (CYP2C19 substrate) | Lowest of all PPIs |
| FAERS Reports | 163,009 (18.6% death-associated) | 206,212 (14.4% death-associated) |
| Available Forms | Capsules, orally disintegrating tablets | Tablets, IV injection |
| Primary Indications | GERD, duodenal ulcers, H. pylori | GERD, stress ulcer prophylaxis, Zollinger-Ellison |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both PPIs deplete identical nutrients through the same proton pump mechanism — supplementation is the same for either drug. The meaningful difference is drug interaction safety. Pantoprazole's minimal CYP2C19 inhibition makes it the gold standard for patients on clopidogrel, where other PPIs can reduce antiplatelet efficacy and increase cardiac event risk. Lansoprazole's 77 CTD gene interactions versus pantoprazole's 22 indicate broader off-target effects, and its moderate CYP interaction potential limits use in polypharmacy. FAERS data is nuanced: pantoprazole has more total reports (206,212 vs 163,009) reflecting its status as the most-prescribed PPI, but a lower death-associated rate (14.4% vs 18.6%). For patients on blood thinners or multiple medications, pantoprazole is the clear winner. For patients who need an orally disintegrating option or slightly higher bioavailability, lansoprazole has practical advantages.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 77 gene interactions for lansoprazole, 2,298 disease associations; 22 gene interactions for pantoprazole, 547 disease associations
- [2]ChEMBL bioactivity database: 137 RCTs for lansoprazole; 109 RCTs for pantoprazole across GI indications
- [3]FAERS (FDA Adverse Event Reporting System): 163,009 lansoprazole reports (18.6% death-associated); 206,212 pantoprazole reports (14.4% death-associated)
- [4]PharmGKB pharmacogenomics database: CYP2C19 interaction profiles — pantoprazole classified as lowest risk among PPIs
- [5]PubMed PMID 20232555 — Gilard M et al. Influence of omeprazole and pantoprazole on clopidogrel antiplatelet action. J Am Coll Cardiol. 2008;51(3):256-260
Check your medications
Check Free →